MedinCell S.A. (EPA:MEDCL)

Market Cap	1.05B
Revenue (ttm)	27.73M
Net Income (ttm)	-18.44M
Shares Out	33.09M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,496
Average Volume	161,474
Open	31.70
Previous Close	31.60
Day's Range	30.20 - 31.74
52-Week Range	12.00 - 39.68
Beta	1.03
RSI	41.55
Earnings Date	Dec 9, 2025

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 131
• Stock Exchange: Euronext Paris
• Ticker Symbol: MEDCL

Financial Performance

In 2024, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2023.